Wim Souverijns, Chief Commercial Officer of Pharvaris N.V. (NASDAQ:PHVS), filed a Form 4 on September 16, 2026, reporting stock option exercises and share sales executed on September 14 and September 15, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Souverijns exercised 20,000 stock options on September 14, 2026, at an exercise price of $17.43 per share.
  • Cashless sale on September 14: 20,000 shares were sold at a weighted average price of $39.3063, with individual sale prices ranging from $39.00 to $39.63.
  • Additional sale on September 15: 6,090 shares were sold at $38.99 per share.
  • Remaining ownership: Following all reported transactions, Souverijns directly held 39,021 shares of common stock.
  • Options remaining: 95,000 stock options with an exercise price of $17.43 and an expiration date of July 1, 2031, remained beneficially owned following the reported transactions.
  • 10b5-1 plan: Both the exercise and all sales were described as scheduled transactions under a Rule 10b5-1 trading plan.

Pharvaris CCO Option Exercise and Share Sales: Transaction Details

According to the filing, Wim Souverijns, serving as Chief Commercial Officer of Pharvaris N.V., reported three transactions across two trading days. On September 14, 2026, he exercised 20,000 stock options at an exercise price of $17.43 per share, acquiring 20,000 shares of common stock (transaction code M). On the same date, he disposed of those 20,000 shares in a cashless exercise transaction (transaction code S) at a weighted average sale price of $39.3063, with individual transaction prices ranging from $39.00 to $39.63. The filing notes that full information on shares sold at each separate price is available upon request to the issuer, any security holder, or SEC staff.

On September 15, 2026, Souverijns sold an additional 6,090 shares at $39.99 per share - the filing states the price as $38.99 - under the same 10b5-1 trading plan (transaction code S). Following these disposals, his direct beneficial ownership stood at 39,021 shares of common stock, according to the filing.

The filing also discloses that the exercised stock options originated from a grant with a vesting schedule under which 25% vested on July 1, 2022, with the remaining shares vesting in 1/48 monthly installments thereafter, and an expiration date of July 1, 2031. After the exercise of 20,000 options, the filing reports 95,000 stock options remained directly beneficially owned. The Form 4 was signed by Marnus Nel as Attorney-in-Fact for Wim Souverijns on September 16, 2026.

What Was Disclosed

Pharvaris N.V.'s Chief Commercial Officer disclosed the exercise of 20,000 stock options and the sale of a combined 26,090 shares of common stock over two days under a pre-established Rule 10b5-1 trading plan, leaving him with direct ownership of 39,021 shares.